Other Species / Isoforms
  NFATC2IP (human)      LTP 

LTP (Low Throughput Papers) : The number of records in which this modification site was determined using methods other than discovery mass spectrometry.

 HTP 

HTP (High Throughput Papers): The number of records in which this modification site was assigned using ONLY proteomic discovery mass spectrometry.

 
S12-p
VGKRGRWsGGSGAGR
0 1
NFATC2IP (human) VGKRGRWsGGSGAGR S12-p
NFATC2IP (mouse) LRGRGPRSRGGRGAR S12
NFATC2IP (rat) LRRRGPRSRGGRASR S12
S37-p
RRPRAQRsPSRGTLD
0 2
NFATC2IP (human) RRPRAQRsPSRGTLD S37-p
NFATC2IP (mouse) RCPRARQSPARLIPD S34
NFATC2IP (rat) RCPRAPRSPTRLIPD S37
T52-p
VVSVDLVtDsDEEIL
0 3
NFATC2IP (human) VVSVDLVtDsDEEIL T52-p
NFATC2IP (mouse) TVLVDLVsDsDEEVL S49-p
NFATC2IP (rat) TVLVDLVsDsDEEVL S52-p
S54-p
SVDLVtDsDEEILEV
0 3
NFATC2IP (human) SVDLVtDsDEEILEV S54-p
NFATC2IP (mouse) LVDLVsDsDEEVLEV S51-p
NFATC2IP (rat) LVDLVsDsDEEVLEV S54-p
S84-p
EPPGPVAsRDNsNsD
Upstream
0 9
Treatment
  • BI2536
NFATC2IP (human) EPPGPVAsRDNsNsD S84-p
NFATC2IP (mouse) RLPAPAKPEQDsDsD P75
NFATC2IP (rat) RLPAPAAPEQDsDsD P79
S88-p
PVAsRDNsNsDsEGE
0 22
NFATC2IP (human) PVAsRDNsNsDsEGE S88-p
NFATC2IP (mouse) PAKPEQDsDsDsEGA S79-p
NFATC2IP (rat) PAAPEQDsDsDsEGA S83-p
S90-p
AsRDNsNsDsEGEDR
0 24
NFATC2IP (human) AsRDNsNsDsEGEDR S90-p
NFATC2IP (mouse) KPEQDsDsDsEGAAE S81-p
NFATC2IP (rat) APEQDsDsDsEGAAE S85-p
S92-p
RDNsNsDsEGEDRRP
0 29
NFATC2IP (human) RDNsNsDsEGEDRRP S92-p
NFATC2IP (mouse) EQDsDsDsEGAAEGP S83-p
NFATC2IP (rat) EQDsDsDsEGAAEGP S87-p
Y126-p
EAPLVPVysGkVKSS
0 2
NFATC2IP (human) EAPLVPVysGkVKSS Y126-p
NFATC2IP (mouse) EAPVVPVySGKVQSS Y117-p
NFATC2IP (rat) EAPVVPVYSGKVQSS Y120
S127-p
APLVPVysGkVKSSL
0 6
NFATC2IP (human) APLVPVysGkVKSSL S127-p
NFATC2IP (mouse) APVVPVySGKVQSSL S118
NFATC2IP (rat) APVVPVYSGKVQSSL S121
K129-ub
LVPVysGkVKSSLRL
0 1
NFATC2IP (human) LVPVysGkVKSSLRL K129-ub
NFATC2IP (mouse) VVPVySGKVQSSLNL K120
NFATC2IP (rat) VVPVYSGKVQSSLNL K123
K129-sm
LVPVysGkVKSSLRL
0 1
NFATC2IP (human) LVPVysGkVKSSLRL K129-sm
NFATC2IP (mouse) VVPVySGKVQSSLNL K120
NFATC2IP (rat) VVPVYSGKVQSSLNL K123
K145-ub
PDDLSLLkLYPPGDE
0 1
NFATC2IP (human) PDDLSLLkLYPPGDE K145-ub
NFATC2IP (mouse) PDNSSLLKLCPSEPE K136
NFATC2IP (rat) PDNSSLLKLCPSEPE K139
S168-p
SGLYHEGsPsPGsPW
Upstream
0 4
Treatment
  • AZD1152
  • nocodazole
  • ZM447439
NFATC2IP (human) SGLYHEGsPsPGsPW S168-p
NFATC2IP (mouse) GSSPSEDDALPSGSP D159
NFATC2IP (rat) SGSPPSEDALPPGSP D161
S170-p
LYHEGsPsPGsPWkT
Upstream
0 5
Treatment
  • AZD1152
  • nocodazole
  • ZM447439
NFATC2IP (human) LYHEGsPsPGsPWkT S170-p
NFATC2IP (mouse) SPSEDDALPSGSPWR L161
NFATC2IP (rat) SPPSEDALPPGSPWK L163
S173-p
EGsPsPGsPWkTKLR
Upstream
0 8
Treatment
  • AZD1152
  • nocodazole
  • ZM447439
NFATC2IP (human) EGsPsPGsPWkTKLR S173-p
NFATC2IP (mouse) DDALPSGSPWRKKLR S165
NFATC2IP (rat) EDALPPGSPWKKKLR S167
K176-ub
PsPGsPWkTKLRTKD
0 1
NFATC2IP (human) PsPGsPWkTKLRTKD K176-ub
NFATC2IP (mouse) under review -
NFATC2IP (rat) LPPGSPWKKKLRKKH K170
T190-p
DKEEKKKtEFLDLDN
0 1
NFATC2IP (human) DKEEKKKtEFLDLDN T190-p
NFATC2IP (mouse) EKEEKKMEEFPDQDI E183
NFATC2IP (rat) EKEEKKMEEFPDQDI E185
S198-p
EFLDLDNsPLsPPsP
0 14
NFATC2IP (human) EFLDLDNsPLsPPsP S198-p
NFATC2IP (mouse) EFPDQDIsPLPQPSS S191-p
NFATC2IP (rat) EFPDQDISPLPQPSS S193
S201-p
DLDNsPLsPPsPRTk
0 10
NFATC2IP (human) DLDNsPLsPPsPRTk S201-p
NFATC2IP (mouse) DQDIsPLPQPSSRNK P194
NFATC2IP (rat) DQDISPLPQPSSRNK P196
S204-p
NsPLsPPsPRTkSRT
Upstream
0 39
Treatment
  • anti-CD3
  • dasatinib
  • metastatic potential
  • nocodazole
NFATC2IP (human) NsPLsPPsPRTkSRT S204-p
NFATC2IP (mouse) IsPLPQPSSRNKSRK S197
NFATC2IP (rat) ISPLPQPSSRNKSRK S199
K208-ac
sPPsPRTkSRTHTRA
0 1
NFATC2IP (human) sPPsPRTkSRTHTRA K208-ac
NFATC2IP (mouse) PQPSSRNKSRKHTEA K201
NFATC2IP (rat) PQPSSRNKSRKHTEA K203
K218-sm
THTRALKkLsEVNkR
0 1
NFATC2IP (human) THTRALKkLsEVNkR K218-sm
NFATC2IP (mouse) KHTEALQKLREVNKR K211
NFATC2IP (rat) KHTEALQKLREVNKR K213
K218-m1
THTRALKkLsEVNkR
0 1
NFATC2IP (human) THTRALKkLsEVNkR K218-m1
NFATC2IP (mouse) KHTEALQKLREVNKR K211
NFATC2IP (rat) KHTEALQKLREVNKR K213
S220-p
TRALKkLsEVNkRLQ
Upstream
0 4
Regulatory protein:
  • PRKD1 (human)
Treatment
  • nocodazole
NFATC2IP (human) TRALKkLsEVNkRLQ S220-p
NFATC2IP (mouse) TEALQKLREVNKRLQ R213
NFATC2IP (rat) TEALQKLREVNKRLQ R215
K224-ub
KkLsEVNkRLQDLRs
0 1
NFATC2IP (human) KkLsEVNkRLQDLRs K224-ub
NFATC2IP (mouse) QKLREVNKRLQDLRS K217
NFATC2IP (rat) QKLREVNKRLQDLRS K219
S231-p
kRLQDLRsCLsPKPP
0 1
NFATC2IP (human) kRLQDLRsCLsPKPP S231-p
NFATC2IP (mouse) KRLQDLRSCLsPKQH S224
NFATC2IP (rat) KRLQDLRSCLSPKQH S226
S234-p
QDLRsCLsPKPPQGQ
0 2
NFATC2IP (human) QDLRsCLsPKPPQGQ S234-p
NFATC2IP (mouse) QDLRSCLsPKQHQSP S227-p
NFATC2IP (rat) QDLRSCLSPKQHQSP S229
T261-p
EGPTLPEtPRLFPLk
0 13
NFATC2IP (human) EGPTLPEtPRLFPLk T261-p
NFATC2IP (mouse) EGPVLPQSSRLFTLK S254
NFATC2IP (rat) EGSVLPQNPRLFTLK N256
K268-ub
tPRLFPLkIRCRADL
0 1
NFATC2IP (human) tPRLFPLkIRCRADL K268-ub
NFATC2IP (mouse) SSRLFTLKIRCRADL K261
NFATC2IP (rat) NPRLFTLKIRCRADL K263
S300-p
MATHLGVsPSRILLL
Upstream
0 5
Treatment
  • nocodazole
NFATC2IP (human) MATHLGVsPSRILLL S300-p
NFATC2IP (mouse) MANHLGVSPNRILLL S293
NFATC2IP (rat) MASHLGVSPNRILLL S295
T311-p
ILLLFGEtELsPtAt
0 3
NFATC2IP (human) ILLLFGEtELsPtAt T311-p
NFATC2IP (mouse) ILLLFGESELSPTAT S304
NFATC2IP (rat) ILLLFGETELSPTAT T306
S314-p
LFGEtELsPtAtPRT
Upstream
0 8
Treatment
  • nocodazole
NFATC2IP (human) LFGEtELsPtAtPRT S314-p
NFATC2IP (mouse) LFGESELSPTATPST S307
NFATC2IP (rat) LFGETELSPTATPRT S309
T316-p
GEtELsPtAtPRTLK
0 4
NFATC2IP (human) GEtELsPtAtPRTLK T316-p
NFATC2IP (mouse) GESELSPTATPSTLK T309
NFATC2IP (rat) GETELSPTATPRTLK T311
T318-p
tELsPtAtPRTLKLG
Upstream
0 5
Treatment
  • nocodazole
NFATC2IP (human) tELsPtAtPRTLKLG T318-p
NFATC2IP (mouse) SELSPTATPSTLKLG T311
NFATC2IP (rat) TELSPTATPRTLKLG T313
S338-p
DCVVLTSsPEAtETS
0 4
NFATC2IP (human) DCVVLTSsPEAtETS S338-p
NFATC2IP (mouse) DCVVLASSSEATETS S331
NFATC2IP (rat) DCVVLASSSEDTETS S333
T342-p
LTSsPEAtETSQQLQ
0 1
NFATC2IP (human) LTSsPEAtETSQQLQ T342-p
NFATC2IP (mouse) LASSSEATETSQELR T335
NFATC2IP (rat) LASSSEDTETSQELR T337
K357-sm
LRVQGKEkHQTLEVs
0 1
NFATC2IP (human) LRVQGKEkHQTLEVs K357-sm
NFATC2IP (mouse) LRVQGKEKHQMLEIs K350
NFATC2IP (rat) LRVQGKEKHQMLEIS K352
S364-p
kHQTLEVsLsRDsPL
0 2
NFATC2IP (human) kHQTLEVsLsRDsPL S364-p
NFATC2IP (mouse) KHQMLEIsLSPDsPL S357-p
NFATC2IP (rat) KHQMLEISLSPDSPL S359
S366-p
QTLEVsLsRDsPLKt
0 5
NFATC2IP (human) QTLEVsLsRDsPLKt S366-p
NFATC2IP (mouse) QMLEIsLSPDsPLKV S359
NFATC2IP (rat) QMLEISLSPDSPLKV S361
S369-p
EVsLsRDsPLKtLMS
Upstream
0 25
Treatment
  • EGF
  • nocodazole
NFATC2IP (human) EVsLsRDsPLKtLMS S369-p
NFATC2IP (mouse) EIsLSPDsPLKVLMS S362-p
NFATC2IP (rat) EISLSPDSPLKVLMS S364
T373-p
sRDsPLKtLMSHYEE
0 2
NFATC2IP (human) sRDsPLKtLMSHYEE T373-p
NFATC2IP (mouse) SPDsPLKVLMSHYEE V366
NFATC2IP (rat) SPDSPLKVLMSHYEE V368
S385-p
YEEAMGLsGRkLsFF
0 1
NFATC2IP (human) YEEAMGLsGRkLsFF S385-p
NFATC2IP (mouse) YEEAMGLSGHKLSFF S378
NFATC2IP (rat) YEEAMGLSGHKLSFF S380
K388-ub
AMGLsGRkLsFFFDG
0 2
NFATC2IP (human) AMGLsGRkLsFFFDG K388-ub
NFATC2IP (mouse) AMGLSGHKLSFFFDG K381
NFATC2IP (rat) AMGLSGHKLSFFFDG K383
K388-sm
AMGLsGRkLsFFFDG
0 1
NFATC2IP (human) AMGLsGRkLsFFFDG K388-sm
NFATC2IP (mouse) AMGLSGHKLSFFFDG K381
NFATC2IP (rat) AMGLSGHKLSFFFDG K383
S390-p
GLsGRkLsFFFDGTk
Upstream
0 18
Treatment
  • BI2536
  • ischemia
  • nocodazole
NFATC2IP (human) GLsGRkLsFFFDGTk S390-p
NFATC2IP (mouse) GLSGHKLSFFFDGTK S383
NFATC2IP (rat) GLSGHKLSFFFDGTK S385
K397-sm
sFFFDGTkLSGRELP
0 1
NFATC2IP (human) sFFFDGTkLSGRELP K397-sm
NFATC2IP (mouse) SFFFDGTKLSGKELP K390
NFATC2IP (rat) SFFFDGTKLSGKELP K392